scholarly journals 100 Activation of A2B adenosine receptor normalizes filaggrin and caspase-14 levels in a murine model of epidermal hyperplasia

2021 ◽  
Vol 141 (10) ◽  
pp. S165
Author(s):  
A. Marín-Castejón ◽  
M. Marco-Bonilla ◽  
J. Arasa ◽  
R. Andrés ◽  
M. Terencio ◽  
...  
PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e40584 ◽  
Author(s):  
Hillary Johnston-Cox ◽  
Milka Koupenova ◽  
Dan Yang ◽  
Barbara Corkey ◽  
Noyan Gokce ◽  
...  

Author(s):  
Hong-xia Li ◽  
Xiao-yan Liang ◽  
Jiong-he Wu ◽  
Ya-ping Yuan ◽  
Yue Gao ◽  
...  

2010 ◽  
Vol 186 (2) ◽  
pp. 1097-1106 ◽  
Author(s):  
Yang Zhou ◽  
Daniel J. Schneider ◽  
Eva Morschl ◽  
Ling Song ◽  
Mesias Pedroza ◽  
...  

2012 ◽  
Vol 32 (suppl_1) ◽  
Author(s):  
Hillary A Johnston-Cox ◽  
Barbara Corkey ◽  
Katya Ravid

The A2b adenosine receptor (A2bAR) is a G-protein coupled receptor that, upon binding of adenosine, activates adenylyl cyclase and mediates downstream effects through secondary messengers, including cyclic 3’5’ AMP (cAMP) and Ca ++ . We have previously demonstrated that A2bAR knockout (KO) KO mice, post-high fat diet (HFD) develop a type 2 diabetic (T2D) phenotype, evidenced by elevated plasma insulin and glucose. Pancreatic islets from A2bAR KO mice demonstrated insulin hypersecretion post-4 weeks HFD, and high glucose challenge. To further understand the underlying mechanism, we focused on the contribution of the pancreatic A2bAR to this phenomnena. cAMP has been demonstrated to be a significant amplifier of glucose-stimulated insulin secretion. Through the use of A2bAR KO islets and diet-induced stress, we identified a new dual role for cAMP in mediating insulin secretion, dependent on cAMP level and duration. Short exposure to elevated cAMP indeed causes insulin hypersecretion. cAMP has, however, also a downregulating effect on the expression of GLUT2 mRNA and protein, which has the potential to inhibit insulin secretion. Thus, A2bAR short and long-term signaling in the pancreas play an important role in insulin homeostasis.


2008 ◽  
Vol 75 (2) ◽  
pp. 562-569 ◽  
Author(s):  
Stefania Gessi ◽  
Eleonora Fogli ◽  
Valeria Sacchetto ◽  
Katia Varani ◽  
Stefania Merighi ◽  
...  

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 1051 ◽  
Author(s):  
Ángelo Torres ◽  
Katherin Muñoz ◽  
Yessica Nahuelpán ◽  
Angelo-Paolo R. Saez ◽  
Pablo Mendoza ◽  
...  

Diabetic nephropathy (DN) is considered the main cause of kidney disease in which myofibroblasts lead to renal fibrosis. Macrophages were recently identified as the major source of myofibroblasts in a process known as macrophage–myofibroblast transition (MMT). Adenosine levels increase during DN and in vivo administration of MRS1754, an antagonist of the A2B adenosine receptor (A2BAR), attenuated glomerular fibrosis (glomerulosclerosis). We aimed to investigate the association between A2BAR and MMT in glomerulosclerosis during DN. Kidneys/glomeruli of non-diabetic, diabetic, and MRS1754-treated diabetic (DM+MRS1754) rats were processed for histopathologic, transcriptomic, flow cytometry, and cellular in vitro analyses. Macrophages were used for in vitro cell migration/transmigration assays and MMT studies. In vivo MRS1754 treatment attenuated the clinical and histopathological signs of glomerulosclerosis in DN rats. Transcriptomic analysis demonstrated a decrease in chemokine-chemoattractants/cell-adhesion genes of monocytes/macrophages in DM+MRS1754 glomeruli. The number of intraglomerular infiltrated macrophages and MMT cells increased in diabetic rats. This was reverted by MRS1754 treatment. In vitro cell migration/transmigration decreased in macrophages treated with MRS1754. Human macrophages cultured with adenosine and/or TGF-β induced MMT, a process which was reduced by MRS1754. We concluded that pharmacologic blockade of A2BAR attenuated some clinical signs of renal dysfunction and glomerulosclerosis, and decreased intraglomerular macrophage infiltration and MMT in DN rats.


Sign in / Sign up

Export Citation Format

Share Document